Grant: Operating Grant
University of British Columbia
$100,000.00
Biomarkers for Chronic Graft-Versus-Host disease
FY 2008-09
Summary
In 2003, approximately 13,700 people world-wide received an allogeneic Blood and Marrow Transplantation (BMT) as a life saving procedure. Of those transplant recipients, >1900 died of graft-versus-host disease (GVHD). The chronic form of GVHD (cGVHD) now occurs in about 50% of all allogeneic BMT and its treatment is limited by a poor ability to diagnose, risk stratify, and evaluate response due to a poor understanding of the underlying biological mechanisms. This current proposal strikes at these primary limitations by utilizing a comprehensive approach to validate biomarkers that will lead to improved ability to assign treatment and develop new therapeutic approaches to cGVHD.
Department
Program
Operating Grant
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
183787
Name
Schultz Kirk R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Biomarkers for Chronic Graft-Versus-Host disease
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Biomarkers; Blood And Marrow Transplantation; Graft-Versus-Host Disease
Abstract
In 2003, approximately 13,700 people world-wide received an allogeneic Blood and Marrow Transplantation (BMT) as a life saving procedure. Of those transplant recipients, >1900 died of graft-versus-host disease (GVHD). The chronic form of GVHD (cGVHD) now occurs in about 50% of all allogeneic BMT and its treatment is limited by a poor ability to diagnose, risk stratify, and evaluate response due to a poor understanding of the underlying biological mechanisms. This current proposal strikes at these primary limitations by utilizing a comprehensive approach to validate biomarkers that will lead to improved ability to assign treatment and develop new therapeutic approaches to cGVHD.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schultz, Kirk R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
